Bristol-Myers Squibb (Germany)

P1.100. Impact of Immunotherapy Introduction on Real-World Treatment Patterns for Advanced Esophageal Cancer: A Retrospective Database Cohort Study From Japan

Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background Treatment of advanced esophageal cancer (EC) has evolved with immune checkpoint inhibitors (ICIs), including nivolumab or pembrolizumab plus doublet chemotherapy (IO-chemo) and nivolumab plus ipilimumab...